This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Emery-Dreifuss muscular dystrophy (scapuloperoneal muscular dystrophy with early contractures)Emery-Dreifuss Muscular Dystrophy (EDMD)

Contents and key points
ItemDetails
A. Classification codesICD-10: G71.0 | Special Copayment Reduction: V012 | Coverage period: 5 years
B. SynonymsEmery-Dreifuss muscular dystrophy (EDMD), scapuloperoneal muscular dystrophy with early contractures, emerin-deficient muscular dystrophy (EDMD1), lamin A/C-deficient muscular dystrophy (EDMD2)
C. Adult onsetModerate likelihood of first onset in adulthood — early joint contractures and muscle weakness begin in childhood, but cardiac complications (conduction abnormalities, atrial fibrillation) mainly appear in adulthood (20s~40s), with a risk of sudden death
1. HistoryDescribed by Emery and Dreifuss in 1966 as an X-linked muscular dystrophy; emerin gene (EMD) discovered in 1994; LMNA mutations identified as the cause of AD EDMD in 1999
2. CausesMutations in the EMD gene (emerin, X-linked recessive, EDMD1) or the LMNA gene (lamin A/C, autosomal; AD EDMD2, AR EDMD3); nuclear envelope protein deficiency
3. GeneticsEDMD1: X-linked recessive (EMD); EDMD2: autosomal dominant (LMNA); EDMD3: autosomal recessive (LMNA); variants in other genes such as FHL1, TMEM43, SUN1, SYNE1, SYNE2 also reported
4. General epidemiologyPrevalence about 0.13~0.3 per 100,000; incidence about 1~2 per 1,000,000 births; EDMD1 mainly affects males; EDMD2 affects males and females equally
5. PathophysiologyEmerin/lamin A/C deficiency → nuclear envelope structural instability → damage to muscle nuclei vulnerable to mechanical stress → muscle fiber necrosis; involvement of electrical conduction system cells (fibrosis) → arrhythmias, ventricular assist device needed
6. SymptomsEarly joint contractures (neck, elbows, ankles), scapuloperoneal muscle weakness and atrophy, cardiac conduction abnormalities (atrial fibrillation, bradycardia), risk of sudden death; the combination of the triad is characteristic
7. SignsContractures of the neck, elbows, and ankles, weakness of the shoulder and lower limb muscles, asymmetric scapular winging, heart rate abnormalities (bradycardia, irregular pulse), ECG abnormalities (PR prolongation, atrioventricular block)
8. ScreeningRecognition of the triad of scapuloperoneal weakness + early joint contractures + ECG abnormalities; serum CK (mildly elevated), ECG, echocardiography, emerin immunostaining
9. DiagnosisMuscle biopsy (emerin immunostaining: absent in EDMD1), EMD/LMNA genetic testing, 24-hour Holter ECG, cardiac MRI, nerve conduction studies
10. TreatmentMusculoskeletal: physical therapy, orthoses; cardiac: permanent pacemaker, ICD (preferred in LMNA type); heart failure: standard pharmacotherapy; heart transplantation; future gene therapy research
11. PrognosisCardiac complications are the main cause of death; high risk of malignant ventricular arrhythmias and sudden death in the LMNA type; sudden death preventable with pacemaker/ICD; muscle weakness progresses slowly
12. PreventionGenetic counseling; family screening (ECG, genetic testing); prevention of sudden death by early ICD implantation; early rehabilitation to prevent joint contractures; periodic cardiac monitoring
References10 key references (including PMID/DOI)

1. History

Emery-Dreifuss muscular dystrophy (EDMD) was named in 1966, when Alan Emery and Friedrich Dreifuss reported an X-linked muscular dystrophy occurring over several generations in a family in Virginia. At the time, the disease was described as a separate entity because, unlike the Duchenne type, it was characterized by a triad of relatively mild muscle weakness, early joint contractures, and cardiac conduction abnormalities.

In 1994, Bione et al. discovered the EMD gene, located on the long arm of the X chromosome (Xq28), and its product, the emerin protein, and confirmed that this protein is a nuclear envelope protein located in the inner nuclear membrane. This was a landmark discovery that introduced the new concept that nuclear envelope protein deficiency causes muscular dystrophy and heart disease. In 1999, Bonne et al. showed that the cause of the autosomal dominant form of EDMD (EDMD2) is mutations in the LMNA gene, which encodes lamin A/C. The LMNA gene was subsequently found to be associated with many other diseases (dilated cardiomyopathy, lipodystrophy, progeria, etc.), and these were collectively established under the concept of "laminopathy." Since the 2000s, mutations in genes encoding LINC complex proteins, such as SYNE1, SYNE2 (nesprin 1 and 2), SUN1, and SUN2, have also been found to be associated with the EDMD phenotype.

2. Causes

EDMD is caused by mutations in genes for proteins that make up the nuclear envelope protein complex (LINC complex: Linker of Nucleoskeleton and Cytoskeleton). The inner nuclear membrane proteins emerin and lamin A/C are the main causative proteins.

3. Genetics

EDMD is classified by mode of inheritance as follows.

Genetic testing is performed with an NGS panel (including EDMD-related genes). On muscle biopsy, negative emerin immunostaining in EDMD1 is a rapid diagnostic clue.

4. General epidemiology

EDMD is a rare disease. Prevalence is estimated at about 0.13~0.3 per 100,000 population, and incidence is about 1~2 per 1,000,000 births. EDMD1 (EMD mutations) and EDMD2 (LMNA mutations) are the most common genotypes, together accounting for about 50% or more of all EDMD. Accurate prevalence is difficult to determine because patients with mild symptoms may go undiagnosed or be classified as having other muscular dystrophies.

EDMD1, with X-linked recessive inheritance, mainly affects males; female carriers are generally asymptomatic, but cardiac involvement has rarely been reported. EDMD2 is autosomal dominant and affects males and females equally, and is characterized by a relatively later age of onset and more prominent cardiac involvement. It occurs worldwide and is not limited to any particular region or ethnicity. Patients with LMNA-related cardiomyopathy (with mild or no EDMD musculoskeletal involvement) are actually more common and may also be included in the broad spectrum of EDMD2.

5. Pathophysiology

The pathophysiology of EDMD is destabilization of nuclear envelope structure due to deficiency or dysfunction of nuclear envelope proteins (emerin, lamin A/C). This is particularly devastating in muscle and cardiomyocytes exposed to mechanical stress.

Mechanism of nuclear envelope structural instability: Emerin and lamin A/C form a lattice structure called the nuclear lamina beneath the inner nuclear membrane, which is responsible for maintaining nuclear shape and mechanical strength. Lamin A/C is linked to the cytoplasmic cytoskeleton (actin, intermediate filaments, microtubules) through the LINC (Linker of Nucleoskeleton and Cytoskeleton) complex. When this linkage is broken, mechanical forces generated during muscle contraction concentrate on the nucleus, causing nuclear envelope rupture and DNA damage.

Muscle cell mechanism: Repetitive mechanical stress during muscle contraction damages the nuclear envelope and induces muscle fiber necrosis. Because satellite cell function also depends on lamin A/C, reduced regenerative capacity also contributes to the progression of the muscular dystrophy. As a result, selective atrophy occurs particularly in the periscapular muscles and calf muscles, which are under high mechanical stress.

Cardiac conduction system mechanism: With LMNA mutations, lamin A/C deficiency in cells of the atria, atrioventricular node, and conduction fibers (His-Purkinje system) causes cell death and fibrosis, resulting in conduction disorders (atrial fibrillation, complete atrioventricular block). In LMNA-related cardiomyopathy, the risk of ventricular arrhythmias and sudden death is high. Abnormal mechanosensitive signal transduction (MAPK, mTOR) related to nuclear envelope instability of cardiomyocytes also contributes to the progression of cardiomyopathy.

6. Symptoms

The classic clinical triad of EDMD is ① early joint contractures, ② scapuloperoneal muscle weakness and atrophy, and ③ cardiac conduction abnormalities and arrhythmias. In some cases all three components are clear, and in others only some components are prominent.

Joint contractures: Often appear before muscle weakness. Elbow flexion contractures (fixed in a flexed position), ankle equinus contractures, and limited neck extension are characteristic. Onset from elementary school age (5~15 years) is common. A rigid spine may also be present, which contributes to respiratory restriction.

Muscle weakness and atrophy: A scapuloperoneal distribution, with preferential weakness of the periscapular muscles (deltoid, biceps, trapezius) and the lower limb peroneal and tibialis anterior muscles (distal lower leg), is typical. Progression is slow, and ambulation is maintained for a relatively long time. CK is mildly elevated (2~10 times normal), markedly lower than in the Duchenne type.

Cardiac complications: Often appear in adulthood (usually in the 20s~40s, some in early adolescence). Atrial fibrillation, atrial flutter, complete atrioventricular block, and sick sinus syndrome are characteristic. In the LMNA type, the risk of malignant ventricular arrhythmias such as ventricular tachycardia and ventricular fibrillation and of sudden death is particularly high. When dilated cardiomyopathy is present, symptoms of heart failure (dyspnea, edema) appear.

7. Signs

On physical examination, the triad of early joint contractures, scapuloperoneal muscle weakness, and cardiac conduction abnormalities strongly suggests EDMD.

Joint examination: Inability to fully extend the elbows (flexion contractures), limited ankle dorsiflexion (equinus contractures), limited neck flexion (limited cervical flexion). Joint contractures generally appear before or at the same time as muscle weakness.

Muscle strength and musculoskeletal examination: Winging scapula, limited shoulder abduction, distal lower limb weakness (tendency to foot drop). Early on, weakness of the proximal upper limbs and distal lower limbs is prominent. CK is normal or mildly elevated (markedly lower than in the Duchenne and Becker types).

Cardiac examination: Irregular pulse (atrial fibrillation), bradycardia, jugular venous distension (in heart failure), abnormal heart sounds. The ECG shows PR interval prolongation, atrial fibrillation, atrioventricular block, left bundle branch block, etc. Signs of heart failure (pulmonary crackles, edema) are evaluated by auscultation.

8. Screening

Screening for EDMD begins with clinical recognition of the triad. EDMD should be actively suspected in patients with a combination of childhood elbow and ankle joint contractures, scapuloperoneal muscle weakness, and ECG abnormalities.

Serum CK: Normal or mildly elevated (2~10 times the upper limit of normal). Being markedly lower than in the Duchenne type (20~100 times normal or more) is a distinguishing point.

Electrocardiogram (ECG): Performed in all patients with suspected EDMD. PR prolongation, atrial fibrillation/flutter, atrioventricular block, right/left bundle branch block, ST changes, etc. are evaluated. When clinically suspected, 24-hour Holter monitoring is performed even without ECG abnormalities.

Echocardiography: Evaluates left ventricular function (EF), wall motion abnormalities, and the presence of myocardial hypertrophy or dilation.

Emerin immunostaining: In EDMD1, emerin is absent on muscle biopsy or skin biopsy (in all cells, including leukocytes). It is a rapid and relatively simple screening method.

9. Diagnosis

EDMD is confirmed by integrating the clinical triad, immunopathology, and genetic testing.

Muscle biopsy: Emerin immunostaining (loss of nuclear envelope emerin in EDMD1, normal in EDMD2), histopathology (nonspecific dystrophic pattern; fiber size variation, internal nuclei, fibrosis). Lamin A/C immunostaining is generally normal in EDMD2. Nuclear envelope irregularities may be observed on electron microscopy.

Genetic testing: Direct sequencing of the EMD gene (confirms EDMD1), direct sequencing of the LMNA gene (confirms EDMD2/3). If negative, testing is expanded with an NGS panel (including FHL1, TMEM43, SYNE1, SYNE2, SUN1, SUN2).

Cardiac testing package: 12-lead ECG, 24-hour Holter ECG, echocardiography, cardiac MRI (evaluation of myocardial fibrosis and fatty infiltration, LGE-CMR). If needed, an electrophysiology study (EPS) evaluates the risk of ventricular arrhythmias.

Electromyography: Myopathic pattern (small-amplitude, polyphasic, early recruitment). Neurogenic changes may also be observed in some cases. Nerve conduction studies are normal.

MRI: Evaluating the pattern of fatty infiltration and atrophy of the periscapular and distal lower limb muscles on muscle MRI helps classify the muscular dystrophy.

10. Treatment

There is no curative treatment for the musculoskeletal complications of EDMD, and management of cardiac complications is the most important treatment area, directly linked to survival.

Cardiac treatment:

Musculoskeletal treatment: Physical therapy (maintaining joint range of motion, preventing worsening of contractures), orthoses (ankle-foot orthosis, AFO; prevention of foot drop), night splints (relief of elbow contractures). When spinal rigidity is severe, noninvasive ventilatory support may be needed to maintain respiratory function.

Treatments under investigation: Gene therapy (adeno-associated virus-mediated emerin or lamin A/C gene delivery), inhibition of MAPK signaling in lamin A/C-deficient cells, etc. are being studied but have not yet reached clinical application.

11. Prognosis

The musculoskeletal complications of EDMD progress relatively slowly, and ambulation is often maintained until after middle age. However, cardiac complications are the main cause of death and determine prognosis.

In EDMD1 (EMD mutations), atrial fibrillation and atrioventricular block are relatively common, but the risk of ventricular arrhythmias is lower than in EDMD2. However, because cases of sudden death have been reported, cardiac follow-up is essential. Cardiac involvement is more severe in EDMD2 (LMNA mutations). Nonsustained ventricular tachycardia, reduced left ventricular function, and LMNA mutation type (especially non-missense mutations) are independent predictors of malignant ventricular arrhythmias and sudden death. Because sudden death still occurs in LMNA-type patients with only a pacemaker implanted, the decision on ICD implantation is important. Appropriate cardiac intervention (ICD implantation, heart failure pharmacotherapy) can significantly reduce cardiac-related mortality.

12. Prevention

Prevention of EDMD itself is achieved through genetic counseling and prenatal diagnosis. However, prevention of life-threatening complications (especially cardiac complications) is clinically most important.

Genetic counseling: In families of confirmed patients, the risk according to the mode of inheritance is explained and genetic testing is offered. In EDMD1, the mother is a carrier and 50% of sons are affected. Because cardiac involvement can also occur in female carriers, cardiac follow-up is recommended. In EDMD2, 50% of the children of an affected parent are affected.

Family screening: In families of diagnosed EDMD patients, EMD or LMNA genetic testing and ECG are performed regularly. Early detection of cardiac abnormalities in genetically affected asymptomatic family members is key to preventing sudden death.

Prevention of sudden death: In LMNA-type EDMD, the current recommended trend is to lower the threshold for early ICD implantation and implant it prophylactically. The risk of sudden death is clearly explained to patients and families, and the benefits and risks of ICD implantation are discussed.

Prevention of joint contractures: To delay the early development of joint contractures as much as possible, regular physical therapy, night splints, and stretching exercises are started in childhood.

References

  1. Emery AE, Dreifuss FE. Unusual type of benign X-linked muscular dystrophy. J Neurol Neurosurg Psychiatry. 1966;29(4):338-342. PMID: 6007224
  2. Bione S, Maestrini E, Rivella S, et al. Identification of a novel X-linked gene responsible for Emery-Dreifuss muscular dystrophy. Nat Genet. 1994;8(4):323-327. PMID: 7894480
  3. Bonne G, Di Barletta MR, Varnous S, et al. Mutations in the gene encoding lamin A/C cause autosomal dominant Emery-Dreifuss muscular dystrophy. Nat Genet. 1999;21(3):285-288. PMID: 10080180
  4. Granger B, Gueneau L, Drouin-Garraud V, et al. Modifier locus of the skeletal muscle involvement in Emery-Dreifuss muscular dystrophy. Hum Genet. 2011;129(2):149-159. PMID: 21057802
  5. van Berlo JH, de Voogt WG, van der Kooi AJ, et al. Meta-analysis of clinical characteristics of 299 carriers of LMNA gene mutations: do lamin A/C mutations portend a high risk of sudden death? J Mol Med. 2005;83(1):79-83. PMID: 15551023
  6. Wahbi K, Ben Yaou R, Gandjbakhch E, et al. Development and validation of a new risk prediction score for life-threatening ventricular tachyarrhythmias in laminopathies. Circulation. 2019;140(4):293-302. PMID: 31155909
  7. Bhatt M, et al. Emery-Dreifuss Muscular Dystrophy Type 1 is associated with a high risk of malignant ventricular arrhythmias and end-stage heart failure. Eur Heart J. 2023;44(48):5064-5073. DOI: 10.1093/eurheartj/ehad539
  8. Arbustini E, Pilotto A, Repetto A, et al. Autosomal dominant dilated cardiomyopathy with atrioventricular block: a lamin A/C defect-related disease. J Am Coll Cardiol. 2002;39(6):981-990. PMID: 11897440
  9. Sanna T, Dello Russo A, Toniolo D, et al. Cardiac features of Emery-Dreifuss muscular dystrophy caused by lamin A/C gene mutations. Eur Heart J. 2003;24(24):2227-2236. PMID: 14659774
  10. Meune C, Van Berlo JH, Anselme F, et al. Primary prevention of sudden death in patients with lamin A/C gene mutations. N Engl J Med. 2006;354(2):209-210. PMID: 16407527